Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors,prompting scientists and doctors to exploit this strategy to treat other tumor types.Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies.Relapse remains the main cause of treatment failure,especially for patients with intermediate or high risk stratification.Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect,which unfortunately puts the patient at risk of serious complications,such as graft-versus-host disease.Although the identification of an ideal target antigen for AML is challenging,CAR T therapy remains a highly promising strategy for AML patients,particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease.In this review,we focus on the most recent and promising advances in CAR T therapies for AML.